USA flag logo/image

An Official Website of the United States Government

NOVEL HIGH THROUGHPUT PLATFORM FOR SCREENING CYTOCHROME P450 INDUCTION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43ES019807
Solicitation Year:
2011
Solicitation Topic Code:
NIEHS
Solicitation Number:
PA10-050
Small Business Information
ORIGINUS, INC.
3970 VARSITY DRIVE ANN ARBOR, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: NOVEL HIGH THROUGHPUT PLATFORM FOR SCREENING CYTOCHROME P450 INDUCTION
Agency: HHS
Contract: 1R43ES019807-01
Award Amount: $222,421.00
 

Abstract:

DESCRIPTION (provided by applicant): Metabolism of administered drugs is determined by expression and activity of drug-metabolizing enzymes, such as cytochrome (CYP) P450 enzymes. These P450s are subject to inhibition and sometimes induction by xenobiotics, leading to possible pharmacokinetic drug-drug interactions between co-administrated drugs. Recognizing the problem, the FDA has issued a Draft Guidance for Industry Drug Interaction Studies, which advice at a minimum in vitro induction evaluation of CYP1A2 and CYP3A4. The importance of evaluating CYP2B6 induction has recently been recognized as well. The gold standard of P450 induction in vitro testing is the determination of enzymatic activity in freshly isolated human hepatocytes. However, availability and individual variability of human hepatocytes as well as inability to discriminate between P450 inhibition and induction in this system complicates the evaluation. The induction of P450s by xenobiotics is mediated by ligand-activated nuclear receptors,including PXR, AhR and CAR. Thus, reporter gene assays for nuclear receptors mediating induction of P450s are considered valid methods of drug evaluation in vitro. Many pharmaceutical industries and some CROs use PXR transactivation assays and very few evaluate AhR activity. There is no commercially available assay for CAR. However, combinations of several nuclear receptors and other transcription factors are needed to induce the expression of specific P450s by all known inducers. The goal of this proposal includes the design and implementation of a novel application of Originus' STEP (Surface Transfection and Expression Protocol) technology for safety testing of novel drug candidates. During Phase I, we will develop sophisticated STEP platforms for simultaneous evaluation of CYP1A2, CYP3A4 and CYP2B6 transcirptional regulation using reporter gene assays in human hepatic cell lines. Secreted alkaline phosphatase (SEAP) gene will be used as a reporter under the control of each human CYP upstream regulatory sequences. STEP co-transfection of the different CYP-SEAP reporters and single or relevant combinations of xenobiotic-activated receptors will be optimized to test SEAP response by a set of inducers at multiple time points in 96-well microplates. Milestonesfor Phase I are the production and beta-testing of the prototypes of STEP platforms (individually or combined) with appropriate assay robustness and reproducibility well-to-well, plate-to-plate and batch-to-batch. These CYP P450 induction platforms will be available for toxicological screening of drugs early in the drug discovery process by high throughput screening laboratories in industry and academia, or as simple assay kits for small laboratory use at a modest cost. During Phase II, we will extend thestudies to evaluate other inducible CYP P450s, expand the spectrum of nuclear receptors tested, and to further develop cell-based assays of relevant allelic variants of the xenobiotic-activated receptors. In addition, we plan to develop STEP assay platforms for pathway profiling of CYP induction. PUBLIC HEALTH RELEVANCE: Drug safety is one of the major factors for compound attrition during clinical development. Simple assays for fast evaluation of metabolism and toxicology of compounds are urgently needed to minimize patient risks and improve the success rate of new molecular entities early in the drug discovery pipeline. The goal of this proposal is to use Originus' proprietary technology, STEP, to develop platforms for in vitro evaluation of drug candidates that may induce certain hepatic enzymes (cytochrome P450s) triggering drug-drug interactions and compromising the health of the patient.

Principal Investigator:

Maria I. Morano
734-913-8791
imorano@originusinc.com

Business Contact:

Joseph J. Norton
734-913-8792
jnorton@originusinc.com
Small Business Information at Submission:

ORIGINUS, INC.
3970 VARSITY DRIVE ANN ARBOR, MI -

EIN/Tax ID: 138357686
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No